Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Healthy Chinese Subjects Aged 18 to 59 Years

NCT03344029 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03344029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03344029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Healthy Chinese Subjects Aged 18 to 59 Years
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
November 3, 2017
Completion date
May 22, 2018
Enrollment
1,600 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

flu, influenza